iloperidone · Vanda Pharms Inc · NDA 022192
Fanapt
Earliest generic entry, as listed · earliest of 7 marketed strengths
28 Dec 2031
Blocked by patent: US 9074254. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 14 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9074254 | use U-1674 | 28 Dec 2031 |
| US 9074256 | use U-1674 | 10 Feb 2031 |
| US 9072742 | use U-1674 | 16 Jan 2031 |
| US 9074255 | use U-1674 | 17 Dec 2030 |
| US 8999638 | use U-1674 | 28 Oct 2030 |
| US 12606869 | use U-4504 | 22 Sep 2030 |
| US 12606869 | use U-4505 | 22 Sep 2030 |
| US 8652776 | use U-1685 | 31 Aug 2030 |
| US 10563259 | use U-4563 | 24 Jul 2030 |
| US 10563259 | use U-4562 | 24 Jul 2030 |
| US 9157121 | use U-1674 | 5 Apr 2030 |
| US 10570453 | use U-4562 | 28 Mar 2028 |
| US 10570453 | use U-4563 | 28 Mar 2028 |
| US 8586610 | use U-1625 | 2 Nov 2027 |
Exclusivities · 1 unexpired
| I-939 | new indication (3 years) | 2 Apr 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 7
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022192 · 001 · RLD | tablet, oral | 1MG | 28 Dec 2031 |
| 022192 · 002 · RLD | tablet, oral | 2MG | 28 Dec 2031 |
| 022192 · 003 · RLD | tablet, oral | 4MG | 28 Dec 2031 |
| 022192 · 004 · RLD | tablet, oral | 6MG | 28 Dec 2031 |
| 022192 · 005 · RLD | tablet, oral | 8MG | 28 Dec 2031 |
| 022192 · 006 · RLD | tablet, oral | 10MG | 28 Dec 2031 |
| 022192 · 007 · RLD | tablet, oral | 12MG | 28 Dec 2031 |